Logo image of XBIO

XENETIC BIOSCIENCES INC (XBIO) Stock Fundamental Analysis

NASDAQ:XBIO - Nasdaq - US9840156023 - Common Stock - Currency: USD

3.06  -0.04 (-1.29%)

Fundamental Rating

3

XBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. While XBIO has a great health rating, there are worries on its profitability. XBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XBIO had negative earnings in the past year.
In the past year XBIO has reported a negative cash flow from operations.
In the past 5 years XBIO always reported negative net income.
XBIO had a negative operating cash flow in each of the past 5 years.
XBIO Yearly Net Income VS EBIT VS OCF VS FCFXBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

XBIO has a Return On Assets (-57.38%) which is in line with its industry peers.
With a Return On Equity value of -65.93%, XBIO perfoms like the industry average, outperforming 57.12% of the companies in the same industry.
Industry RankSector Rank
ROA -57.38%
ROE -65.93%
ROIC N/A
ROA(3y)-46.96%
ROA(5y)-50.4%
ROE(3y)-52.04%
ROE(5y)-55.19%
ROIC(3y)N/A
ROIC(5y)N/A
XBIO Yearly ROA, ROE, ROICXBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIO Yearly Profit, Operating, Gross MarginsXBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

XBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XBIO remains at a similar level compared to 1 year ago.
The number of shares outstanding for XBIO has been increased compared to 5 years ago.
There is no outstanding debt for XBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XBIO Yearly Shares OutstandingXBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
XBIO Yearly Total Debt VS Total AssetsXBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

XBIO has an Altman-Z score of -37.46. This is a bad value and indicates that XBIO is not financially healthy and even has some risk of bankruptcy.
XBIO's Altman-Z score of -37.46 is on the low side compared to the rest of the industry. XBIO is outperformed by 93.24% of its industry peers.
There is no outstanding debt for XBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.46
ROIC/WACCN/A
WACC10.11%
XBIO Yearly LT Debt VS Equity VS FCFXBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 7.37 indicates that XBIO has no problem at all paying its short term obligations.
XBIO has a better Current ratio (7.37) than 70.11% of its industry peers.
A Quick Ratio of 7.37 indicates that XBIO has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.37, XBIO is doing good in the industry, outperforming 70.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.37
Quick Ratio 7.37
XBIO Yearly Current Assets VS Current LiabilitesXBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.55% over the past year.
XBIO shows a decrease in Revenue. In the last year, the revenue decreased by -1.64%.
Measured over the past years, XBIO shows a very strong growth in Revenue. The Revenue has been growing by 162.66% on average per year.
EPS 1Y (TTM)6.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.69%
Revenue 1Y (TTM)-1.64%
Revenue growth 3Y29.17%
Revenue growth 5Y162.66%
Sales Q2Q%-3.57%

3.2 Future

The Earnings Per Share is expected to grow by 21.32% on average over the next years. This is a very strong growth
Based on estimates for the next years, XBIO will show a small growth in Revenue. The Revenue will grow by 4.35% on average per year.
EPS Next Y-28.59%
EPS Next 2Y34.96%
EPS Next 3Y21.32%
EPS Next 5YN/A
Revenue Next Year27.27%
Revenue Next 2Y2.25%
Revenue Next 3Y4.35%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
XBIO Yearly Revenue VS EstimatesXBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
XBIO Yearly EPS VS EstimatesXBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XBIO. In the last year negative earnings were reported.
Also next year XBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIO Price Earnings VS Forward Price EarningsXBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIO Per share dataXBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as XBIO's earnings are expected to grow with 21.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.96%
EPS Next 3Y21.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENETIC BIOSCIENCES INC

NASDAQ:XBIO (5/13/2025, 8:06:58 PM)

3.06

-0.04 (-1.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07
Earnings (Next)08-11 2025-08-11
Inst Owners6.49%
Inst Owner Change3.68%
Ins Owners1.21%
Ins Owner Change0%
Market Cap4.71M
Analysts43.33
Price TargetN/A
Short Float %0.55%
Short Ratio0.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-164.71%
Min EPS beat(2)-233.33%
Max EPS beat(2)-96.08%
EPS beat(4)2
Avg EPS beat(4)-81.06%
Min EPS beat(4)-233.33%
Max EPS beat(4)3.2%
EPS beat(8)6
Avg EPS beat(8)-23.09%
EPS beat(12)7
Avg EPS beat(12)-15.71%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)78.25%
Min Revenue beat(2)-19.71%
Max Revenue beat(2)176.22%
Revenue beat(4)2
Avg Revenue beat(4)41.36%
Min Revenue beat(4)-22.95%
Max Revenue beat(4)176.22%
Revenue beat(8)5
Avg Revenue beat(8)34.63%
Revenue beat(12)9
Avg Revenue beat(12)38.81%
Revenue beat(16)13
Avg Revenue beat(16)63.8%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-390.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)55.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.88
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-2.57
EYN/A
EPS(NY)-3.3
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS1.62
BVpS3.9
TBVpS3.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.38%
ROE -65.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.96%
ROA(5y)-50.4%
ROE(3y)-52.04%
ROE(5y)-55.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.37
Quick Ratio 7.37
Altman-Z -37.46
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.69%
EPS Next Y-28.59%
EPS Next 2Y34.96%
EPS Next 3Y21.32%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.64%
Revenue growth 3Y29.17%
Revenue growth 5Y162.66%
Sales Q2Q%-3.57%
Revenue Next Year27.27%
Revenue Next 2Y2.25%
Revenue Next 3Y4.35%
Revenue Next 5YN/A
EBIT growth 1Y7.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.29%
EBIT Next 3Y-34.25%
EBIT Next 5YN/A
FCF growth 1Y31.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.52%
OCF growth 3YN/A
OCF growth 5YN/A